Quercetin Supplementation Does not alter Antioxidantstatus in Humans by NC DOCKS at Appalachian State University et al.
Archived version from NCDOCKS Institutional Repository http://libres.uncg.edu/ir/asu/ 
Quercetin Supplementation
Does not alter Antioxidantstatus in Humans
Authors
R. ANDREW SHANELY, AMY M. KNAB, DAVID C. NIEMAN, FUXIA JIN, STEVEN R. 
MCANULTY, & MICHAEL J. LANDRAM
Abstract
This study measured the influence of ingesting quercetin on plasma measures for oxidative stress and antioxidant 
capacity. Male and female subjects (n = 1002) varying in age (18–85 years) and body mass index (BMI) (16.7–52.7 kg/
m2) were studied. Subjects were randomized to one of three groups using double-blinded methods: placebo, 500 mg 
or 1000 mg quer- cetin/day with 125 mg or 250 mg vitamin C/day, respectively. Pre- and post-study fasting blood 
samples show that plasma quercetin increased in a dose-responsive manner. The pattern of change in plasma F2-
isoprostanes, oxidized low density lipoprotein, reduced glutathione, ferric reducing ability of plasma (FRAP) and 
oxygen radical absorbance capacity (ORAC) did not differ between supplementation groups or after adjustment for 
gender, age, BMI and disease status. In summary, quercetin supplementation over 12 weeks in doses of 500 mg or 
1000 mg/day significantly increased plasma quercetin levels, but had no influence on several measures of oxidative 
stress and antioxidant capacity
R. ANDREW SHANELY, AMY M. KNAB, DAVID C. NIEMAN, FUXIA JIN, STEVEN R. MCANULTY, & MICHAEL 
J. LANDRAM (2010) "Quercetin Supplementation Does not alter Antioxidantstatus in Humans" Free Radical Research 
44:224-231 Version of Record available @ (DOI: 10.3109/10715760903407293)
Quercetin supplementation does not alter antioxidant status in humans 
R. ANDREW SHANELY, AMY M. KNAB, DAVID C. NIEMAN, FUXIA JIN, 
STEVEN R. MCANULTY, & MICHAEL J. LANDRAM 
North Carolina Research Campus, Appalachian State University, Human Performance Laboratory, Plants for Human Health 
Building, 600 LaureateWay, Kannapolis, NC 28081, USA 
Abstract 
This study measured the influence of ingesting quercetin on plasma measures for oxidative stress and antioxidant capacity. 
Male and female subjects (n = 1002) varying in age (18–85 years) and body mass index (BMI) (16.7–52.7 kg/m2) were 
studied. Subjects were randomized to one of three groups using double-blinded methods: placebo, 500 mg or 1000 mg quer- 
cetin/day with 125 mg or 250 mg vitamin C/day, respectively. Pre- and post-study fasting blood samples show that plasma 
quercetin increased in a dose-responsive manner. The pattern of change in plasma F2-isoprostanes, oxidized low density 
lipoprotein, reduced glutathione, ferric reducing ability of plasma (FRAP) and oxygen radical absorbance capacity (ORAC) 
did not differ between supplementation groups or after adjustment for gender, age, BMI and disease status. In summary, 
quercetin supplementation over 12 weeks in doses of 500 mg or 1000 mg/day significantly increased plasma quercetin levels, 
but had no influence on several measures of oxidative stress and antioxidant capacity. 
Keywords: Quercetin, ferric reducing ability of plasma (FRAP), oxygen radical absorbance capacity (ORAC), F2-
isoprostanes, oxidized low density lipoprotein (LDL), glutathione, antioxidant, oxidative stress. 
Introduction 
Polyphenols are nutrients present in a wide variety of 
edible plants [1]. The best defined group of polyphe- 
nols in the human diet are the flavonoids, which con- 
tain a three-ring structure with two aromatic centres 
and a central oxygenated heterocycle [2,3]. Flavonols 
are the most widespread dietary flavonoids, of which 
quercetin is the most prominent (3,3’,4’,5,7-pentahy- 
droxyflavone) [3]. Dietary flavonols such as quercetin 
have been reported to have physiological effects, i.e. 
antioxidative [4,5], anti-inflammatory [6–8], anti-patho- 
genic [9,10], anti-viral [11–13], anti-microbial [14], 
anti-carcinogenic [15], cardioprotective [16] and 
mitochondrial biogenesis [17] activities and thus pro- 
vide significant potential in the study of improving 
human health. 
The richest food sources of quercetin are onions, hot 
peppers, curly kale, blueberries, apples, tea and broccoli 
[1,2]. Reports of total flavonol intake range from 13–64 
mg/day, of which quercetin comprises ~ 75% [2,18]. 
Humans can absorb substantial amounts of quercetin 
in a dose-dependent fashion [19] with a reported half- 
life of 11–28 h [3,20,21]. Notably, chronic, high-dose 
quercetin ingestion by humans or rodents has not been 
found to be detrimental [22,23], but an optimal dose 
has yet to be characterized [24, 25]. In fact, epidemio- 
logical studies report that a diet high in quercetin is 
associated with a decreased risk for ischemic heart dis- 
ease [26,27] and common types of cancer [15,27]. 
Quercetin is a powerful antioxidant and free radical 
scavenger, as demonstrated from in vitro studies 
[28–31]. Animal studies have yielded important infor- 
mation regarding the antioxidant capability of quer- 
cetin. For example, quercetin administered to rodents 
results in increased antioxidant activity [32], decreased 
lipid peroxidaxtion [5,33–35] and inhibition of LDL 
oxidation [36]. A few small-scale human quercetin 
supplementation studies have produced conflicting 
results regarding quercetin’s potential antioxidant 
effects. One study of obese subjects found that 6 
weeks of quercetin supplementation decreased 
oxidized LDL [37] but all other human studies 
report no effect on a variety of measures of 
antioxidant capacity and oxidative stress [19,38–
42]. 
Several reports indicate that oxidative stress is 
increased among obese and elderly individuals and 
those with chronic disease [43–45]. Boots et al. [41] 
hypothesized that quercetin supplementation may be 
more efficacious among individuals at risk for 
oxidative stress. Thus, the primary objective of this 
study was to measure the influence of two 
quercetin doses (500 or 1000 mg/day) on plasma 
oxidative stress and antioxidant capacity in a 
large community group (n = 1002) varying 
widely in age, BMI and disease status. We 
hypothesized that quercetin would have a positive 
effect on antioxidant status, especially in those 
presumed to have elevated oxidative stress and 
depressed plasma antioxidant capacity. 
Materials and methods 
Subjects 
Male and female subjects (n = 1023), 18–85 years of 
age, were recruited via mass advertising from the 
community. Half of the subjects were studied during 
a 12-week period from January to April 2008 and the 
second half from August to November 2008. Subjects 
had to be non-institutionalized and women were 
excluded if pregnant or lactating. No other exclusion 
criteria were employed and both diseased and non- 
diseased subjects were admitted into the study, with 
monitoring of disease status and medication use. 
Written informed consent was obtained from each 
subject and the Appalachian State University institu- 
tional review board approved all experimental proce- 
dures. During recruitment, subjects were stratified by 
gender (~ 40% male, 60% female), age (40% young 
adult (18–40 years of age), 40% middle-aged (41–65) 
and 20% elderly (65 and over)) and body mass index 
(BMI) groups (33% normal (18.5–24.9), 33% 
overweight (25–29.9) and 33% obese (2: 30 kg/m2)) 
to ensure representation of these various sub-groups. 
Subjects agreed to avoid any other supplements 
containing quercetin; no other restrictions were placed 
on diet, supplement usage or medications. 
Research design 
Subjects were randomized to one of three groups: 
Q-500 (500 mg quercetin/day), Q-1000 (1000 mg 
quercetin/day) or placebo (PL). Supplements were 
administered utilizing double blinded procedures. 
Subjects ingested two soft chew supplements twice 
daily (upon awakening, and between 2 pm and the 
last meal of the day) during the 12-week study period. 
Supplements were prepared by Nutravail Technolo- 
gies (Chantilly, VA) with Quercegen Pharma (New- 
ton, MA) and were soft, individually wrapped chews 
(5.3 g/piece) that contained either 125 or 250 mg 
quercetin, 125 or 250 mg vitamin C (ascorbic acid 
and sodium ascorbate), 5 or 10 mg niacin and 20 
kilocalories of sugars in a carnauba wax, soy lecithin, 
corn starch, glycerine and palm oil base coloured with 
FD&C yellow #5 and #6. Placebo supplements were 
prepared exactly the same way minus the quercetin, 
ascorbic acid and sodium ascorbate and niacin. Data 
from Quercegen Pharma (unpublished data, personal 
communication, Tom Lines) indicate that the 
bioavailability of quercetin is enhanced with vitamin 
C and niacin and thus this study tested whether the 
combination of quercetin, vitamin C and niacin had 
an influence on the outcome measures. 
Subjects started supplementing after the first blood 
sample and continued for 12 weeks. Subjects 
completed a monthly log to verify adherence to the 
supplementation regimen, physical activity and 
diet status, change in disease status and medication 
use, gastrointestinal (constipation, heartburn, 
bloating, diarrhea, nausea, vomiting), skin (rash, 
dryness, flushing), allergy and mental (energy, 
headache, stress, focus/concentration)  symptoms. 
Outcome measures 
Two weeks prior to the first lab visit for the study, 
subjects provided demographic and lifestyle habit 
information via the survey posted on SurveyMonkey. 
com (Portland, OR). Height was measured with a 
stadiometer and body mass and body composition 
determined using a Tanita bioelectrical impedance 
(BIA) scale (Tanita, Arlington Heights, IL). Blood 
samples were taken after an overnight fast in the 
morning (7–9 am) before and after the 12-week 
supplementation period. Once separated, plasma 
samples were imme- diately flash-frozen in liquid 
nitrogent, stored at 80°C and analyzed for the 
outcome measures described below. Unless 
specified otherwise all chemicals were purchased 
from Sigma Aldrich (St Louis, MO). 
Plasma quercetin. Plasma quercetin was measured as 
previously described [25]. Briefly, total plasma 
quercetin (quercetin and its primary conjugates) 
from heparin treated blood was measured following 
solid- phase extraction via reversed–phase HPLC 
with UV detection. Quercetin conjugates were 
hydrolysed by incubating 500 µL plasma aliquots 
with 10 µL 10% DL-dithiothreitol solution, 50 µL 
0.58 M acetic acid, 50 µL of a mixture of -
glucuronidase/arylsulphatase and crude extract 
from Helix pomatia (Roche Diagnostics 
Corporation, Indianapolis, IN) for 2 h at 
37C. Chromatographic analysis was performed using 
the Ultimate 3000 HPLC-PDA system (Dionex 
Corporation, Sunnyvale, CA) with a Gemini C18 
column (Phenomenex, Torrance, CA). 
Oxidative stress and antioxidant capacity. Plasma F2-
isoprostanes were determined using gas 
chromatography mass spectrometry (GC-MS) 
[46,47]. Plasma was collected from heparinized 
blood, immediately flash- frozen in liquid nitrogen 
and stored at 80°C [47]. Immediately prior to 
assay plasma samples were 
thawed. The samples were used to extract free F2-iso- 
prostanes with deuterated [2H4] prostaglandin F2
(PGF2added as an internal standard. The mixture 
was then added to a C18 Sep Pak column, followed 
by silica solid phase extractions. F2-isoprostanes were 
converted to pentafluorobenzyl esters, subjected to 
thin layer chromatography and converted to trimeth- 
ylsilyl ether derivatives. Samples were analysed by a 
negative ion chemical ionization GC-MS using an 
Agilent 6890N gas chromatography interfaced to an 
Agilent 5975B inert MSD mass spectrometer (Agilent 
Technologies, Inc. Santa Clara, CA). 
Quantification of oxidized low density lipoproteins 
(oxidized LDL) in a sub-group of subjects was per- 
formed as previously described [48,49] using 
standard protocols for a competitive ELISA kit 
(Mercodia Oxidized LDL Competitive Enzyme-
Linked Immunosorbent Assay, Mercodia Inc., 
Sweden). Plasma from EDTA treated blood was 
used accordingto the commercially available 
protocol and absorbance was read at 450 nm. 
Red blood cell reduced glutathione (GSH) was 
assayed in a sub-group of subjects using the Cayman 
Chemical GSH assay kit (#703002, Ann Arbor, MI). 
This assay utilizes an optimized enzymatic recycling 
method, using glutathione reductase to quantify the 
amount of GSH in red blood cells collected from 
heparinized blood. The samples were read at 405 nm 
and reported as M of reduced glutathione per gram 
of haemoglobin [50]. 
Total plasma antioxidant power was determined by 
the ferric reducing ability of plasma (FRAP) assay 
[46,51], a single electron transfer reaction. This assay 
utilizes water-soluble antioxidants native to the plasma 
collected from EDTA treated blood to reduce ferric 
iron to the ferrous form subsequently producing a 
chromogen identifiable at 593 nm. Samples and stan- 
dards are expressed as ascorbate equivalents based on 
an ascorbate standard curve. Intra-assay and inter- 
assay coefficients of variation were less than 5% and 
7%, respectively. 
Oxygen radical absorbance capacity (ORAC) was 
measured in a sub-group of subjects using methods 
described previously [52]. Serial dilutions of 50 µM, 
25 µM, 12.5 µM and 6.25 µM of Trolox (6-hydroxy- 
2,5,7,8-tetramethyl-chroman-2-carboxylic acid) were 
made using phosphate buffer solution and used as 
standards. Fluorescien solution was made by diluting 
800 µL of stock solution into 50 mL phosphate buffer. 
This solution was incubated completely, at 37C, 
prior to use. AAPH solution was made by dissolving 
0.108 g of AAPH (Wako Chemicals, Richmond, VA) 
in 5 mL of phosphate buffer solution (incubated at 
37C prior to use with AAPH) and 20 µL (1.6 mol) 
of AAPH solution was then added to each well 
immediately before reading. The microplate was 
loaded in a ‘forward-then-reverse’ order, with edge 
wells loaded only with phosphate buffer to avoid 
edge effects. Blanks,Trolox standards and samples 
(human plasma from ETDA treated blood) were 
loaded into appro- priate wells, followed by 200 L 
of fluoroscien work- ing solution.The plate was then 
covered and incubated at 37C for at least 20 min, 
followed by the addition of 20 µL AAPH working 
solution. ORAC values were calculated by the 
plate reader (Spectra Max Gemini XPS, Molecular 
Devices) (area under the curve). Excitation 
wavelength was 485 nm and emission 
wavelength was 520 nm. 
Statistical  procedures 
Data were analysed using a 3 (group) X 2 (time) 
repeated measures ANOVA, between groups design, 
with post-hoc analysis using Bonferroni adjusted inde- 
pendent t-tests that contrasted pre- to post-supple- 
mentation changes of Q-500 and Q-1000 with PL 
(p<0.0125). Additional repeated measures ANOVAs 
were conducted by adding categorical covariates to 
the model to test for the influence of gender (male, 
female), BMI (normal<25 kg/m2, overweight 25–29.9 
kg/m2, and obese 2: 30 kg/m2), age (< 40, 40–59, 
2: 60 years) and chronic disease status (with or with- 
out). Data are expressed as means ± SE. 
Results 
Of the 1023 subjects recruited into the study, 1002 
completed all phases of the study. Among the 21 drop- 
outs (seven from the PL group, six from Q-500 and 
eight from Q-1000), 12 failed to take the supplement 
and/or adhere to testing procedures and nine reported 
adverse symptoms from taking the supplement. Fol- 
low-up revealed no consistent pattern of symptoms 
that could be ascribed to taking the quercetin supple- 
ments. Table I shows that subject characteristics did 
not differ significantly between groups. Subjects were 
60% female and 40% male, ranged widely in age, BMI 
and body composition and were predominately Cau- 
casian.Thirty-seven per cent of subjects reported past 
or current history for one or more chronic diseases: 
hypertension (19%), arthritis (16%), cancer (6%), 
cardiovascular disease (4%), diabetes (4%). For all 
subjects combined, F2-isoprostanes were significantly 
Table I. Subject characteristics (n = 1002) (mean ± SE). 
Variable 
Placebo 
n = 335 
M = 123; F = 212 
Q-500 
n = 334 
M = 138; F = 196 
Q-1000 
n = 333 
M = 134; F = 199 
Group (All) 
n = 1002 
M = 395; F = 607 
Age (years) 
Males 43.8 ± 1.5 45.3 ± 1.2 45.5 ± 1.4 46.0 ± 0.5 
Females 47.4 ± 1.1 47.2 ± 1.1 45.2 ± 1.1 (18–85) 
Weight (kg) 
Males 84.8 ± 1.4 85.7 ± 1.2 88.1 ± 1.5 77.2 ± 0.6 
Females 71.2 ± 1.1 71.6 ± 1.2 71.4 ± 1.3 (42.7–157.5) 
Height (m) 
Males 1.77 ± 0.06 1.78 ± 0.04 1.77 ± 0.06 1.70 ± 0.03 
Females 1.64 ± 0.05 1.65 ± 0.05 1.64 ± 0.04 (1.39–2.02) 
BMI (kg/m2) 
Males 27.0 ± 0.4 26.9 ± 0.4 28.1 ± 0.4 26.7±0.2 
Females 26.4 ± 0.4 26.2 ± 0.4 26.4 ± 0.5 (16.7–52.7) 
Body composition (% fat) 
Males 
Females 
22.1 ± 0.8 
34.8 ± 0.7 
22.1 ± 0.7 
34.8 ± 0.7 
24.9 ± 0.8 
33.8 ± 0.7 
30.0 ± 0.4 
(3.4–59.5) 
Education (years) 15.5 ± 0.2 15.5 ± 0.2 15.8 ± 0.2 15.6 ± 0.1 
Marital status 34% single 
53% married 
13% other 
Race 93% white 
2% black 
5% other 
32% single 
60% married 
8% other 
93% white 
2% black 
5% other 
33% single 
55% married 
12% other 
92% white 
4% black 
4% other 
33% single 
56% married 
11% other 
93% white 
3% black 
4% other 
elevated: 16.3% in the obese (n = 244) (48.4 ± 1.1 
pg/mL) vs those with normal weight (n = 435) (41.6 
± 0.6 pg/mL) (p<0.001), but no differences were 
found when accounting for gender, age and disease 
status. FRAP differed significantly between obese 
(+ 13.7%) (614 ± 10.2 mol/L) and normal weight 
(540 ± 6.5 mol/L) subjects (p<0.001). Additionally, 
FRAP was elevated in males (+17.5%) and in sub- 
jects who were older (2: 60 vs< 40 years, +14.9%) 
or diseased (+11.4%) (all p<0.001). 
Plasma quercetin (overnight fasted) in both quercetin 
groups increased significantly above PL levels in a 
dose-responsive manner (interaction effect, p<0.001) 
(Figure 1) and monthly measures (data not shown) 
indicated that the increase peaked during the first 
month and was maintained for 12 weeks. Individuals 
varied widely in their plasma quercetin response to 
supplementation, but increases were not related to gen- 
der, BMI, age or chronic disease status. 
The pattern of change over time between groups 
did not differ significantly for plasma F2-isoprostanes 
(interaction effect, p = 0.280) (Figure 2), oxidized 
LDL (interaction effect, p = 0.831) (Figure 3), GSH 
(interaction effect, p = 0.800) (Figure 4), FRAP 
(interaction effect, p = 0.528) (Figure 5) or ORAC 
(interaction effect, p = 0.525) (Figure 6). Separate 
analyses by gender, BMI, age and chronic disease sta- 
tus failed to find significant differences in the out- 
come measures across Q-500, Q-1000 and PL groups. 
For the sub-group for which oxidized LDL was mea- 
sured, no significant interaction effects were shown 
for LDL-cholesterol or HDL-cholesterol (data not 
shown). 
Discussion 
We found that 12-weeks supplementation with 500 or 
1000 mg quercetin per day significantly increased 
overnight fasted plasma quercetin. However, contrary 
to our hypothesis, the increase in plasma quercetin 
was not associated with significant alterations in 
plasma measures of oxidative stress or antioxidant 
Pre-Study 12-Weeks 
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Placebo (N=333) Q-500 (N=332) Q-1000 (N=329) 
Figure 1. Plasma quercetin concentration was significantly 
increased by 500 mg/d (Q-500) or 1000 mg/d (Q-1000) for 12 
weeks. Plasma quercetin concentration is expressed as g/L. 
p < 0.05 compared to Placebo; †p < 0.05 compared to Q-500. 
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Figure 2. Plasma F2-isoprostanes, a measure of oxidative stress, 
were measured before and after 12 weeks of quercetin 
supplementation, 500 mg/d (Q-500) or 1000 mg/d (Q-1000). 
Plasma F2-isoprostane concentration is expressed as pg/ml. 
 
capacity in community-dwelling adults. Our study 
included a relatively large number of subjects with 
multiple sub-groups. We employed two different 
doses of quercetin and the oxidative stress and 
antioxidant capacity results are in agreement with 
the handful of human studies previously conducted. 
Plasma F2-isoprostane, formed as a result of 
arachidonic acid peroxidation, was unchanged with 12-
weeks of quercetin supplementation; a finding in 
agreement 
with short-term studies conducted by our group 
[40,46] and others [53]. Contrary to our hypothesis, 
plasma F2-isoprostanes were not significantly elevated 
in the older subjects or in those with chronic disease. 
However, plasma F2-isoprostanes were significantly 
elevated in obese subjects, as previously reported by 
others [43,44]. 
Although quercetin supplementation has been 
found to attenuate the ex vivo oxidation of LDL [24], 
our in vivo results suggest that long-term quercetin 
supplementation does not alter the levels of oxidized 
Figure 4. Reduced glutathione (GSH) was determined in red 
blood cells as a measure of antioxidant capacity in a sub-group 
of subjects. GSH was measured before and after 12 weeks of 
quercetin supplementation, 500 mg/d (Q-500) or 1000 mg/d 
(Q-1000). Data are expressed as µM of reduced glutathione per 
gram of haemoglobin (Hg). 
 
LDL in humans, as also reported by Egert et al. [19]. 
However, another study of overweight subjects using 
a cross-over design with a 5-week washout period 
found a 14% decrease in oxidized LDL following 6 
weeks of supplementation with 150 mg quercetin per 
day compared to a 7% decrease during the placebo 
condition [37]. 
We measured the antioxidant capacity of plasma 
using three different methods; GSH, FRAP and 
ORAC. GSH, a non-enzymatic free radical scavenger, 
was unaffected by quercetin supplementation, as pre- 
viously reported by Boots et al. [41]. FRAP assessed 
the reducing capacity of plasma while ORAC assessed 
the radical-scavenging capacity of plasma. Our results 
indicate that quercetin supplementation relative to 
PL does not alter FRAP or ORAC, as previously 
reported by Egert et al. [19] in healthy adults, and by 
our research team in studies of endurance athletes 
[40,46]. FRAP and ORAC as well as other antioxi- 
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Figure 3. Oxidized low density lipoproteins (oxidized LDL), a 
measure of oxidative stress, was measured before and after 12 
weeks of quercetin supplementation, 500 mg/d (Q-500) or 1000 
mg/d (Q-1000) in a sub-group of subjects. Data are expressed as 
units (U) of oxidized LDL/ml. 
Figure 5. The ferric reducing ability of plasma (FRAP) assay was 
used as a measure of total plasma antioxidant power. FRAP was 
measured before and after 12 weeks of quercetin supplementation, 
500 mg/d (Q-500) or 1000 mg/d (Q-1000). Data are expressed as 
ascorbate equivalents (mol/L). 
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12-Weeks strate little evidence of protection from oxidative 
stress, many studies indicate a decrease in disease risk 
and improved antioxidant capacity when foods rich 
in quercetin are consumed in the diet [54]. 
There is increasing support that co-ingestion 
of quercetin with other flavonoids and food 
components improve and extend quercetin’s 
bioavailability and bioactive effects [10,57]. These 
inclue the flavonoid epigallocatechin 3-gallate 
(EGCG) from tea [58], iso- quercetin (quercetin-3-
glucose or hirsutrin) which is 
the glycosylated form of quercetin in onions and other 
Placebo (N=217) Q-500 (N=216) Q-1000 (N=221) 
Figure 6. The oxygen radical absorbance capacity (ORAC) assay 
was used as a measure of total antioxidant power in a sub-group 
of subjects. ORAC was measured before and after 12 weeks 
of quercetin supplementation, 500 mg/d (Q-500) or 1000 mg/d 
(Q-1000). Data are expressed as Trolox equivalents (mol/L). 
 
 
dant capacity assays (e.g. trolox equivalent antioxi- 
dant capacity (TEAC) and total radical-trapping 
antioxidant parameter (TRAP)) measure the contri- 
bution of all reducing and antioxidant substances and 
thus lack specificity [54]. However, our chosen marker 
of oxidative stress and the three measures of antioxi- 
dant capacity used in this study were not affected by 
quercetin ingestion, suggesting that this formulation 
of quercetin does not act as an in vivo antioxidant. 
Interestingly, FRAP was significantly increased in 
obese, male, elderly and diseased subjects, irrespec- 
tive of quercetin intake. This finding suggests that 
FRAP is increased in those under oxidative stress, a 
novel finding that has not been previously reported. 
The FRAP assay is sensitive to ascorbate levels and 
accounts for ~ 15% of the plasma FRAP value [51]. 
ORAC, on the other hand, did not differ between 
sub-groups within our population and is not sensitive 
to ascorbate levels [52,54]. Plasma ascorbate levels 
were not measured in the current study. 
The hypothesis that dietary flavonoids play a sig- 
nificant role as antioxidants in vivo has been chal- 
lenged recently because of the growing realization 
that most flavonoids have low bioavailability and 
undergo extensive metabolism that reduces antioxi- 
dant capacity [39,41,54,55]. After ingestion, querce- 
tin and its methylated derivatives (isorhamnetin, 
tamarixetin) are not present in aglycone form but 
only in the conjugated form (mainly glucuronide and 
sulphate conjugates) in species investigated thus far 
including humans, pigs and rats [55,56]. 
The lack of quercetin-related decreases in oxidative 
stress measures in humans [19,39,40,42,54] is in 
contrast to findings from in vitro experiments [28–31] 
and animal studies [5,32–36] that indicate strong 
antioxidant influences. Loke et al. [55] conducted an 
eloquent in vitro study demonstrating that free quer- 
cetin provides greater protection from oxidative stress 
than its conjugated metabolites found in the plasma. 
While quercetin supplementation studies demon- 
foods, n3-polyunsaturated fatty acids (n3-PUFAs) 
such as eicosapentaenoic acid (EPA) and docosa- 
hexaenoic acid (DHA) [59] and the nutrients vitamins 
C, E and folate [10,60]. In a recent experiment we 
found that 2-weeks ingestion of a mixed flavonoid-fish 
oil supplement significantly decreased acute exercise- 
induced oxidative stress (20% decrease in plasma 
F2-isoprostanes) and inflammation (50% decrease in 
C-reactive protein (CRP), 39% decrease in IL-6) 
compared to quercetin alone or placebo [25]. We are 
currently investigating whether the supplement effects 
found in exercised athletes [25] extends to a group of 
middle-aged and overweight/obese women with 
chronic inflammation and oxidative stress. 
In summary, quercetin supplementation in doses of 
500 mg or 1000 mg/day did not improve antioxidant 
capacity or decrease oxidative stress in a large popula- 
tion of subjects ranging widely in age, BMI and dis- 
ease state. Future research will determine if the 
bioavailability of quercetin and its bioactive effects 
can be augmented by adding other flavonoids (e.g. 
EGCG) and food components [10,58,61].This mixed 
flavonoid supplement approach may be efficacious in 
at risk populations such as obese, older adults with 
chronic oxidative stress and inflammation. 
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